A Comprehensive Comparison of Clinical Presentation and Outcomes of Kidney Transplant Recipients with COVID-19 during Wave 1 versus Wave 2 at a Tertiary Care Center, India
Table 3
Clinical outcome and management of KTRs with COVID-19 in both waves
Parameters
Number (n = 156)
Percentage
Wave 1 (n = 72) n (%)
Wave 2 (n = 84) n (%)
p value
Treatment parameters
Hospitalization
78
50.0
44 (61.1)
34 (40.5)
0.010
Domiciliary
78
50.0
28 (38.8)
50 (59.5)
0.010
Room air management
83
53.2
36 (50.0)
47 (56.0)
0.458
Oxygen with mask
29
17.3
16 (18.6)
13 (15.5)
0.280
Noninvasive ventilator
13
8.3
6 (8.3)
7 (8.3)
1.00
Ventilator
27
17.3
14 (19.4)
13 (15.5)
0.514
Steroid
156
100
72 (100)
84 (100)
1.00
Azithromycin
67
42.9
30 (41.7)
37 (44.0)
0.765
HCQS
9
5.8
7 (9.7)
2 (2.4)
0.082
Ivermectin
105
67.3
40 (55.6)
65 (77.4)
0.004
Doxycycline
102
65.8
38 (53.5)
64 (76.2)
0.003
Tocilizumab
10
6.4
9 (12.5)
1 (1.2)
0.006$
Remdesivir
45
38.8
24 (33.3)
21 (25.0)
0.252
Convalescent plasma
32
20.5
22 (30.6)
10 (11.9)
0.004
Favipiravir
53
34.0
0
53 (63.1)
<0.001$
Fluvoxin
44
28.2
0
44 (52.4)
<0.001$
Nintedanib
8
15.3
1 (1.5)
7 (8.4)
0.070$
Thromboprophylaxis
Antiplatelet
3
1.9
2 (2.8)
1 (1.2)
<0.001$
LMWH
52
33.3
31 (43)
21 (25.0)
OAC
74
47.4
20 (27.8)
54 (64.4)
Not taking
28
17.9
20 (27.8)
8 (9.5)
Antinucleoside drugs
Continued
19
12.1
12 (16.7)
7 (8.3)
0.062$
Dose reduced
5
3.2
4 (5.5)
1 (1.2)
Drug stopped
128
82.0
53 (73.6)
75 (89.2)
Not taking
4
2.6
3 (4.2)
1 (1.2)
CNI drugs (tacrolimus or cyclosporine)
CNI continued
116
74.4
50 (69.4)
66 (78.6)
0.813
CNI dose reduced
2
1.3
1 (1.4)
1 (1.2)
CNI stopped
36
22.5
20 (27.8)
16 (19.0)
Not taking
2
1.3
1 (1.4)
1 (1.2)
AKI and need for dialysis support (CRRT/SLEDD/Intermittent hemodialysis)
Total AKI patients
65
41.7
29 (40.3)
36 (42.9)
0.745
AKI patients needing dialysis
25
16.0
13 (18.1)
12 (14.3)
0.522
Computerized tomographic scanning with CT score (N=67)
